BACKGROUND AND PURPOSE: Prostamides are lipid mediators formed by COX-2-catalysed oxidation of the endocannabinoid anandamide and eliciting effects often opposed to those caused by anandamide. Prostamides may be formed when hydrolysis of anandamide by fatty acid amide hydrolase (FAAH) is physiologically, pathologically or pharmacologically decreased. Thus, therapeutic benefits of FAAH inhibitors might be attenuated by concomitant production of prostamide F2 α . This loss of benefit might be minimized by compounds designed to selectively antagonize prostamide receptors and also inhibiting FAAH. EXPERIMENTAL APPROACH: Inhibition of FAAH by a series of selective antagonists of prostamide receptors, including AGN 204396, AGN 211335 and AGN 211336, was assessed using rat, mouse and human FAAH in vitro, together with affinity for human recombinant CB1 and CB2 receptors. Effects in vivo were measured in a model of formalin-induced inflammatory pain in mice. KEY RESULTS: The prostamide F2 α receptor antagonists were active against mouse and rat FAAH in the low μM range and behaved as non-competitive and plasma membrane-permeant inhibitors. AGN 211335, the most potent inhibitor of rat FAAH (IC50 = 1.2 μM), raised exogenous anandamide levels in intact cells and also bound to cannabinoid CB1 receptors. Both AGN 211335 and AGN 211336 (0.25-1 mg·kg(-1) , i.p.) inhibited the formalin-induced nociceptive response in mice. CONCLUSIONS AND IMPLICATIONS: Synthetic compounds with indirect agonist activity at cannabinoid receptors and antagonist activity at prostamide receptors can be developed. Such compounds could be used as alternatives to selective FAAH inhibitors to prevent the possibility of prostamide F2 α -induced inflammation and pain. LINKED ARTICLES: This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-6.
BACKGROUND AND PURPOSE:Prostamides are lipid mediators formed by COX-2-catalysed oxidation of the endocannabinoidanandamide and eliciting effects often opposed to those caused by anandamide. Prostamides may be formed when hydrolysis of anandamide by fatty acid amide hydrolase (FAAH) is physiologically, pathologically or pharmacologically decreased. Thus, therapeutic benefits of FAAH inhibitors might be attenuated by concomitant production of prostamide F2 α . This loss of benefit might be minimized by compounds designed to selectively antagonize prostamide receptors and also inhibiting FAAH. EXPERIMENTAL APPROACH: Inhibition of FAAH by a series of selective antagonists of prostamide receptors, including AGN 204396, AGN 211335 and AGN 211336, was assessed using rat, mouse and humanFAAH in vitro, together with affinity for human recombinant CB1 and CB2 receptors. Effects in vivo were measured in a model of formalin-induced inflammatory pain in mice. KEY RESULTS: The prostamide F2 α receptor antagonists were active against mouse and ratFAAH in the low μM range and behaved as non-competitive and plasma membrane-permeant inhibitors. AGN 211335, the most potent inhibitor of ratFAAH (IC50 = 1.2 μM), raised exogenous anandamide levels in intact cells and also bound to cannabinoid CB1 receptors. Both AGN 211335 and AGN 211336 (0.25-1 mg·kg(-1) , i.p.) inhibited the formalin-induced nociceptive response in mice. CONCLUSIONS AND IMPLICATIONS: Synthetic compounds with indirect agonist activity at cannabinoid receptors and antagonist activity at prostamide receptors can be developed. Such compounds could be used as alternatives to selective FAAH inhibitors to prevent the possibility of prostamide F2 α -induced inflammation and pain. LINKED ARTICLES: This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-6.
Authors: S Maione; L De Petrocellis; V de Novellis; A Schiano Moriello; S Petrosino; E Palazzo; F Sca Rossi; D F Woodward; V Di Marzo Journal: Br J Pharmacol Date: 2007-02-05 Impact factor: 8.739
Authors: Jeffery J Prusakiewicz; Philip J Kingsley; Kevin R Kozak; Lawrence J Marnett Journal: Biochem Biophys Res Commun Date: 2002-08-23 Impact factor: 3.575
Authors: Allan Weber; Jinsong Ni; Kah-Hiing John Ling; Andrew Acheampong; Diane D-S Tang-Liu; Robert Burk; Benjamin F Cravatt; David Woodward Journal: J Lipid Res Date: 2004-01-16 Impact factor: 5.922
Authors: Chaitanya S Nirodi; Brenda C Crews; Kevin R Kozak; Jason D Morrow; Lawrence J Marnett Journal: Proc Natl Acad Sci U S A Date: 2004-02-06 Impact factor: 11.205
Authors: I Matias; J Chen; L De Petrocellis; T Bisogno; A Ligresti; F Fezza; A H-P Krauss; L Shi; C E Protzman; C Li; Y Liang; A L Nieves; K M Kedzie; R M Burk; V Di Marzo; D F Woodward Journal: J Pharmacol Exp Ther Date: 2004-02-02 Impact factor: 4.030
Authors: Annelot C M van Esbroeck; Antonius P A Janssen; Armand B Cognetta; Daisuke Ogasawara; Guy Shpak; Mark van der Kroeg; Vasudev Kantae; Marc P Baggelaar; Femke M S de Vrij; Hui Deng; Marco Allarà; Filomena Fezza; Zhanmin Lin; Tom van der Wel; Marjolein Soethoudt; Elliot D Mock; Hans den Dulk; Ilse L Baak; Bogdan I Florea; Giel Hendriks; Luciano De Petrocellis; Herman S Overkleeft; Thomas Hankemeier; Chris I De Zeeuw; Vincenzo Di Marzo; Mauro Maccarrone; Benjamin F Cravatt; Steven A Kushner; Mario van der Stelt Journal: Science Date: 2017-06-09 Impact factor: 47.728
Authors: Travis W Grim; Sudeshna Ghosh; Ku-Lung Hsu; Benjamin F Cravatt; Steven G Kinsey; Aron H Lichtman Journal: Pharmacol Biochem Behav Date: 2014-07-21 Impact factor: 3.533